Hi friends
Dr. John Pagel discusses the risks and benefits of ABT-199 and TRU-016 in CLL (chronic lymphocytic leukemia) in an interview from ASH 2013 that I just posted on my blog bkoffman.blogspot.com
I am off to ASCO later this week with an absolutely crazy schedule of interviews, lectures and meetings that I want to bring to the CLL community over the ensuing months.
Stay strong.
Brian
My 1 year CAR-T anniversary and from ASH 2018, Dr. Siddiqi on how CLL treatment has changed.
Your opportunity to suggest questions for Patient Power ASH 2013 Interviews
ASH 2017: Dr. Richard Furman on the importance of MCL-1 in CLL (chronic lymphocytic leukemia)ASH 2016: Dr. Seymour on Combination therapies with venetoclax
Exciting times in CLL: an ASCO 2013 interview with Dr Susan O’Brien
